Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the recipient of a significant increase in short interest in February. As of February 27th, there was short interest totaling 46,346 shares, an increase of 2,371.8% from the February 12th total of 1,875 shares. Based on an average daily trading volume, of 20,337 shares, the days-to-cover ratio is currently 2.3 days. Currently, 1.4% of the shares of the stock are sold short. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 20,337 shares, the days-to-cover ratio is currently 2.3 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Scinai Immunotherapeutics Stock Performance

Shares of NASDAQ:SCNI opened at $0.75 on Thursday. The firm has a market capitalization of $2.60 million, a PE ratio of -0.08 and a beta of 1.89. Scinai Immunotherapeutics has a 52-week low of $0.61 and a 52-week high of $6.18. The firm has a fifty day moving average of $0.84 and a 200 day moving average of $1.10.

Institutional Trading of Scinai Immunotherapeutics

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC raised its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. 58.41% of the stock is owned by hedge funds and other institutional investors.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.